Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.
Botanix Pharmaceuticals has notified the market of the issue of 8.75 million unquoted options, each exercisable at A$0.125 and expiring on 24 December 2029, under an employee incentive scheme. The award of these unlisted options, which are not intended to be quoted on the ASX, is designed to align staff incentives with shareholder value creation and may modestly increase potential future dilution if exercised.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an ASX-listed biopharmaceutical company (code: BOT) focused on developing dermatology and other pharmaceutical products, leveraging advanced drug delivery technologies to address unmet medical needs.
Average Trading Volume: 5,970,656
Technical Sentiment Signal: Sell
Current Market Cap: A$237M
See more insights into BOT stock on TipRanks’ Stock Analysis page.